Biomarin Pharmaceutical Inc annual net income for fiscal TTM was $73 million, a decrease of 79.1% from $349 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $73M | $349M | $427M | $168M | $142M | ($64M) | $854M | ($24M) | ($77M) | ($117M) | ($630M) | ($172M) | ($134M) | ($176M) | ($114M) | ($54M) | $206M | $0M | $31M | ($16M) | ($29M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $45M | $106M | ($47M) | ($31M) | $241M | $186M | $125M | $106M | $107M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BMRN metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All BMRN financial statements → Interactive BMRN charts →
About TickerBase · Data methodology & sources · Privacy · Terms